| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Tumour Immunology Laboratory, Epstein-Barr Virus Unit, Bancroft Centre, Queensland Institute of Medical Research, University of Queensland, Joint Oncology Program, Herston, Australia
For many years, EBV vaccine development efforts have concentrated on the use of structural Ag, gp350, and have been directed toward Ab-mediated blocking virus attachment to the target cell. There is increasing evidence to suggest that the development of neutralizing Abs in vaccinated animals does not always correlate with protection; nevertheless, it has been postulated that gp350-specific T cell-mediated immune responses may have an effector role in protection. This hypothesis has largely remained untested. In the present study, we demonstrate that CTL from acute infectious mononucleosis patients display strong ex vivo reactivity against the EBV structural Ags, gp85 and gp350. Moreover, long-term follow up studies on infectious mononucleosis-recovered individuals showed that these individuals maintain gp350- and gp85-specific memory CTL, albeit at low levels, in the peripheral blood. These results strongly suggest that CTL specific for EBV structural proteins may play an important role in the control of EBV infection during acute infection. More importantly, we also show that prior immunization of HLA A2/Kb transgenic mice with gp350 and gp85 CTL epitopes induced a strong epitope-specific CTL response and afforded protection against gp85- or gp350-expressing vaccinia virus challenge. These results have important implications for future EBV vaccine design and provides evidence, for the first time, that CTL epitopes from EBV structural proteins may be used for establishing strong antiviral immunity against EBV infection.
This article has been cited by other articles:
|
|
 |
|
  M. Urquiza, R. Lopez, H. Patino, J. E. Rosas, and M. E. Patarroyo Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells J. Biol. Chem., October 21, 2005; 280(42): 35598 - 35605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Obar, D. C. Donovan, S. G. Crist, O. Silvia, J. P. Stewart, and E. J. Usherwood T-Cell Responses to the M3 Immune Evasion Protein of Murid Gammaherpesvirus 68 Are Partially Protective and Induced with Lytic Antigen Kinetics J. Virol., October 1, 2004; 78(19): 10829 - 10832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Khanna Predictive Algorithms and T Cell Epitope Mapping J. Immunol., September 1, 2004; 173(5): 2895 - 2895. [Full Text] [PDF]
|
|
|
|
|
|
L. Santodonato, G. D'Agostino, R. Nisini, S. Mariotti, D. M. Monque, M. Spada, L. Lattanzi, M. Paola Perrone, M. Andreotti, F. Belardelli, et al. Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN-{alpha} and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response J. Immunol., May 15, 2003; 170(10): 5195 - 5202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Duraiswamy, M. Sherritt, S. Thomson, J. Tellam, L. Cooper, G. Connolly, M. Bharadwaj, and R. Khanna Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma Blood, April 15, 2003; 101(8): 3150 - 3156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Silins, M. A. Sherritt, J. M. Silleri, S. M. Cross, S. L. Elliott, M. Bharadwaj, T. T. T. Le, L. E. Morrison, R. Khanna, D. J. Moss, et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load Blood, December 15, 2001; 98(13): 3739 - 3744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Catalina, J. L. Sullivan, K. R. Bak, and K. Luzuriaga Differential Evolution and Stability of Epitope-Specific CD8+ T Cell Responses in EBV Infection J. Immunol., October 15, 2001; 167(8): 4450 - 4457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. J. Wang, F. J. Jenkins, L. P. Jacobson, L. A. Kingsley, R. D. Day, Z.-W. Zhang, Y.-X. Meng, P. E. Pellet, K. G. Kousoulas, A. Baghian, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8+ T-cell response to viral lytic cycle proteins Blood, April 15, 2001; 97(8): 2366 - 2373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Usherwood, D. J. Roy, K. Ward, S. L. Surman, B. M. Dutia, M. A. Blackman, J. P. Stewart, and D. L. Woodland Control of Gammaherpesvirus Latency by Latent Antigen-specific CD8+ T Cells J. Exp. Med., September 25, 2000; 192(7): 943 - 952. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
